CHRS · Coherus Oncology, Inc.
$1.20
+0.06 (+5.26%)
At close · Aug 14
Market Cap
$185.40M
Shares
154.50M
Coherus Oncology, Inc. Earnings Call Transcripts
Every quarterly earnings call for Coherus Oncology, Inc. (CHRS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼44.9%
$45.42M
−$86.65M
'22 Q3
22-11-08
▼38.2%
$45.35M
−$58.87M
'22 Q4
23-03-06
▼46%
$32.44M
−$75.73M
'23 Q1
23-05-08
▼2.4%
$58.72M
−$42.87M
'23 Q2
23-08-02
▲64.2%
$74.57M
−$39.64M
'23 Q3
23-11-06
▲101.8%
$91.52M
−$79.65M
'23 Q4
24-03-13
▼92.9%
$2.31M
$102.88M
'24 Q1
24-05-09
▼82.5%
$10.30M
−$12.92M
'24 Q2
24-08-08
▼91.9%
$6.05M
−$10.75M
'24 Q3
24-11-06
▼91.6%
$7.73M
−$50.70M
'24 Q4
25-03-10
▲229.2%
$7.60M
−$56.57M
'25 Q1
25-05-12
▼0.4%
$10.25M
$297.77M
'25 Q2
25-08-07
▲91.2%
$11.57M
−$35.53M
'25 Q3
25-11-06
▲64.9%
$12.75M
−$37.64M
'25 Q4
26-03-09
▲62%
$12.31M
−$38.33M
'26 Q1
26-05-11
LATEST
▲39.5%
$14.31M
−$20.63M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Coherus Oncology, Inc. Earnings Conference Call
Positive tone
TAGMO (CCR8 antibody) clinical development
Biomarker / TIRRI program
CASDOZO/HCC first-line program
Revenue
$14.31M
▲ 39.5% YoY Diluted EPS
$-0.13
▼ 105.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-11
Coherus Oncology, Inc. Q1 FY2026 Earnings Call
Positive tone
Tagmokitug (CCR8) clinical program and data readouts
LOQTORZI commercial trajectory and revenue guidance
Casdozokitug in hepatocellular carcinoma (CATALYST-202)
Revenue
$12.31M
▲ 62% YoY Diluted EPS
$-0.28
▼ 110.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
Q4 2025 Coherus Oncology, Inc. Earnings Conference Call
Confident tone
Lactorsi commercial ramp in MPC
Duration of therapy and persistence on Lactorsi
R&D spend framework and budgetary discipline
Revenue
$12.75M*
▲ 64.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Coherus Oncology, Inc. Q3 FY2025 Earnings Call
Confident tone
CHS-114 CCR8 Treg depleter platform
Combination strategy and LOQTORZI as backbone
Colorectal and other indication expansion
Revenue
$11.57M
▲ 91.2% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Coherus Oncology, Inc. Q2 FY2025 Earnings Call
Confident tone
CHS-114 CCR8 program
LOQTORZI commercial growth
Community oncology adoption
Revenue
$10.25M
▼ 0.4% YoY Diluted EPS
$2.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Coherus Oncology, Inc. Q1 FY2025 Earnings Call
Confident tone
LOQTORZI Commercial Launch
Pipeline Asset CHS-114 (CCR8)
Casdozokitug in Hepatocellular Carcinoma
Revenue
$7.60M
▲ 229.2% YoY Diluted EPS
$2.57
▲ 182.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Coherus Oncology, Inc. Q4 FY2024 Earnings Call
Positive tone
LOQTORZI commercial performance in nasopharyngeal carcinoma
UDENYCA divestiture and balance sheet transformation
Pipeline development and upcoming data readouts
Revenue
$7.73M*
▼ 91.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Coherus Oncology, Inc. Q3 FY2024 Earnings Call
Confident tone
UDENYCA revenue growth and market share
LOQTORZI launch and NPC opportunity
UDENYCA supply interruption and restocking
Revenue
$6.05M
▼ 91.9% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Coherus Oncology, Inc. Q2 FY2024 Earnings Call
Revenue
$10.30M
▼ 82.5% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Coherus Oncology, Inc. Q1 FY2024 Earnings Call
Confident tone
UDENYCA franchise growth
LOQTORZI launch and NPC market
Revenue trajectory and growth expectations
Revenue
$2.31M
▼ 92.9% YoY Diluted EPS
$0.91
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Coherus Oncology, Inc. Q4 FY2023 Earnings Call
Positive tone
UDENYCA franchise growth
LOQTORZI launch and NPC
Pipeline and tumor microenvironment
Revenue
$91.52M*
▲ 101.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Coherus Oncology, Inc. Q3 FY2023 Earnings Call
Revenue
$74.57M
▲ 64.2% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Coherus Oncology, Inc. Q2 FY2023 Earnings Call
Revenue
$58.72M
▼ 2.4% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Coherus Oncology, Inc. Q1 FY2023 Earnings Call
Revenue
$32.44M
▼ 46% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Coherus Oncology, Inc. Q4 FY2022 Earnings Call
Revenue
$45.35M*
▼ 38.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Coherus Oncology, Inc. Q3 FY2022 Earnings Call
Revenue
$45.42M
▼ 44.9% YoY Diluted EPS
$-1.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Coherus Oncology, Inc. Q2 FY2022 Earnings Call
Revenue
$60.15M
▼ 31.4% YoY Diluted EPS
$-0.65
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Coherus Oncology, Inc. Q1 FY2022 Earnings Call
Revenue
$60.12M
▼ 27.6% YoY Diluted EPS
$-1.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Coherus Oncology, Inc. Q4 FY2021 Earnings Call
Revenue
$73.37M*
▼ 33.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Coherus Oncology, Inc. Q3 FY2021 Earnings Call
Revenue
$82.50M
▼ 27.3% YoY Diluted EPS
$-0.49
▼ 248.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Coherus Oncology, Inc. Q2 FY2021 Earnings Call
Revenue
$87.64M
▼ 35.4% YoY Diluted EPS
$-0.40
▼ 157.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Coherus Oncology, Inc. Q1 FY2021 Earnings Call
Revenue
$83.03M
▼ 28.5% YoY Diluted EPS
$-2.37
▼ 593.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Coherus Oncology, Inc. Q4 FY2020 Earnings Call
Revenue
$110.42M*
▼ 10.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Coherus Oncology, Inc. Q3 FY2020 Earnings Call
Revenue
$113.55M
▲ 1.7% YoY Diluted EPS
$0.33
▼ 47.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Coherus Oncology, Inc. Q2 FY2020 Earnings Call
Revenue
$135.67M
▲ 62.6% YoY Diluted EPS
$0.70
▲ 118.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-14
Coherus Oncology, Inc. Q1 FY2020 Earnings Call
Revenue
$116.18M
▲ 213.2% YoY Diluted EPS
$0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Coherus Oncology, Inc. Q4 FY2019 Earnings Call
Revenue
$123.86M
Diluted EPS
$0.53
Gross margin
93.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1512762
CUSIP
19249H103
13F (30d)
142 filings
138 filers
Visit website
Investor relations